Sfoglia per AUTORE
BONI L
Collezione AO Cuneo

  

Items : 28

Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2023 Dec 1;41(34):5263-5273. doi: 10.1200/JCO.23.00506. Epub 2023 Aug 3.

2023
AO Cuneo
ASL Cuneo 1

Pietrantonio F; Boni L; Cremolini C; Fassan M; Zagonel V; Buggin F; Loupakis F; Morano F; Leo S; Zustovich F; Ronzoni M; Granetto C; Antonuzzo L; Arnoldi E; Boscolo G; Frassineti GL; Raimondi A; Pella N; Bergamo F; Cinieri S; Di Donato S; Scartozzi M; Rossini D; Lonardi S; Rasola C; Formica V; Lobefaro R;

Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients. in Journal of the National Cancer Institute / J Natl Cancer Inst. 2022 Mar 8;114(3):400-408. doi: 10.1093/jnci/djab213.

2022
AO Cuneo

Lambertini M; Boni L; Michelotti A; Magnolfi E; Cogoni AA; Mosconi AM; Giordano M; Garrone O; Arpino G; Poggio F; Cinacchi P; Bighin C; Fregatti P; Pronzato P; Blondeaux E; Del Mastro L;

Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2022 Dec;23(12):1571-1582. doi: 10.1016/S1470-2045(22)00632-5. Epub 2022 Nov 10.

2022
AO Cuneo
ASL Città di Torino

Lambertini M; Colantuoni G; Puglisi F; Montemurro F; Bighin C; Correale P; Poletti P; Mansutti M; Alicicco MG; Urracci Y; Gasparro S; Garrone O; Fabi A; Cognetti F; Vaccaro A; Nisticò C; Turletti A; Bisagni G; Rimanti A; Gravina A; De Laurentiis M; Forestieri V; Giuliano M; Blondeaux E; De Placido S; Poggio F; Boni L; Del Mastro L;

Correction to: Surgical treatment of colonic Crohn's disease: a national snapshot study. in Langenbeck's archives of surgery / Langenbecks Arch Surg. 2022 Dec;407(8):3921-3924. doi: 10.1007/s00423-021-02119-7.

2022
AOU Città della Salute di Torino
AO Cuneo
AO Ordine Mauriziano

Spinelli A; Selvaggi F; Romano L; Graziano GMP; Pugliese L; Pietrabissa A; Selvaggi L; Sciaudone G; Peltrini R; Manfreda A; Botti F; Prati M; Boni L; Giuliani A; Sammarco G; Delaini G; Perotti S; Allaix ME; Mistrangelo M; Zaffaroni G; Resegotti A; Bondurri A; Maffioli A; Mineccia M; Calini G; Terrosu G; Vescio G; Gallo G; Impellizzeri H; et alii...

Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. in NPJ breast cancer / NPJ Breast Cancer. 2021 Jun 28;7(1):82. doi: 10.1038/s41523-021-00286-w.

2021
ASL Città di Torino
AO Cuneo
AOU Città della Salute di Torino

De Placido S; Del Mastro L; Cognetti F; Ardizzoni A; Gravina A; Colantuoni G; Gamucci T; Garrone O; Turletti A; Durando A; Bisagni G; Giuliano M; De Laurentiis M; Bighin C; Puglisi F; Gerratana L; Lambertini M; Ceppi M; Boni L; Montemurro F; Russo S;

Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL). in British journal of cancer / Br J Cancer. 2021 Jul;125(2):306. doi: 10.1038/s41416-021-01439-1.

2021
AO Cuneo

Ardizzoni A; Boni L; Tofani L; Brocchi S; Sperandi F; Lamberti G; Colantonio I; Cinieri S; Dazzi C; Longo L; Frassoldati A; Delmonte A; Riccardi F; Cavanna L; Barbieri F; Gelsomino F; Tiseo M;

Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic in Colorectal Disease

2021
AO Cuneo
ASL Cuneo 1

De Nardi P; Frattaruolo C; Mari G; Monteleone M; Confalonieri M; Costanzi A; Fiorini A; Norcini C; Colletti G; Parise P; Acher A; La Torre F; Abbott D; Sarin A; Ozgediz D; Glencer A; Nunez-Garcia B; Choudhry A; Marx W; Abel MK; Boeck M; Chessa A; Tonini V; Sartarelli L; Gori A; Cervellera M; Travaglio E; Sasia D; Rimonda R; et alii...

Final analysis of the PROMISEGIM6 phase III trial assessing GnRH agonist use during chemotherapy as a strategy to preserve ovarian function in premenopausal patients with early breast cancer in Journal of Clinical Oncology

2021
AO Cuneo

Garrone O; Arpino G; Mosconi AM; Lambertini M; Blondeaux E; Del Mastro L; Pronzato P; Bighin C; Fregatti P; Poggio F; Cinacchi P; Giordano M; Cogoni AA; Magnolfi E; Michelotti A; Boni L;

Could fluorescence-guided surgery be an efficient and sustainable option? A SICE (Italian Society of Endoscopic Surgery) health technology assessment summary. in Surgical endoscopy / Surg Endosc. 2020 Jul;34(7):3270-3284. doi: 10.1007/s00464-020-07542-3.

2020
AO Cuneo

Biondi A; Davini F; Bonino MA; Arezzo A; Petz WL; Marano A; Cirocchi R; Boni L; Cassinotti E; Currò G; Rosati R; Elmore U; Baiocchi GL; Molfino S; Lettieri E; Nocco U; Molteni B; Gerardi C; Ferrario L; Foglia E; Vettoretto N; Anania G; Agresta F; Silecchia G;

Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL). in British journal of cancer / Br J Cancer. 2020 Jul;123(1):26-32. doi: 10.1038/s41416-020-0845-3. Epub 2020 Apr 29.

2020
AO Cuneo

Ardizzoni A; Boni L; Tofani L; Brocchi S; Lamberti G; Sperandi F; Colantonio I; Cinieri S; Dazzi C; Longo L; Delmonte A; Frassoldati A; Cavanna L; Riccardi F; Barbieri F; Gelsomino F; Tiseo M;

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. in The Lancet. Oncology / Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.

2020
AOU Città della Salute di Torino
AO Cuneo

Fenocchio E; Mammoliti S; Cupini S; Roselli M; Mambrini A; Ritorto G; Clavarezza M; Carlomagno C; Di Donato S; Ronzoni M; Masi G; Tomasello G; Antonuzzo L; Corallo S; Cordio S; Moretto R; Buonadonna A; Granetto C; Murgioni S; Zaniboni A; Aprile G; Grande R; Marmorino F; Passardi A; Santini D; Tamburini E; Latiano TP; Bordonaro R; Pietrantonio F; et alii...

Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2019 Mar;109:175-182. doi: 10.1016/j.ejca.2018.12.028. Epub 2019 Feb 5.

2019
AO Cuneo

Fontanini G; Lonardi S; Sensi E; Tonini G; Schirripa M; Granetto C; Delfanti S; Di Donato S; Casagrande M; Gemma D; Borelli B; Allegrini G; Murgioni S; Antoniotti C; Dell'Aquila E; Masi G; Salvatore L; Aprile G; Bergamo F; Marmorino F; Cremolini C; Boni L; Falcone A;

Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2019 Dec 1;30(12):1969-1977. doi: 10.1093/annonc/mdz403.

2019
AO Cuneo

Marmorino F; Rossini D; Lonardi S; Moretto R; Zucchelli G; Aprile G; Dell'Aquila E; Ratti M; Bergamo F; Masi G; Urbano F; Ronzoni M; Libertini M; Borelli B; Randon G; Buonadonna A; Allegrini G; Pella N; Ricci V; Boccaccino A; Latiano TP; Cordio S; Passardi A; Tamburini E; Boni L; Falcone A; Cremolini C;

Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC in Journal of Clinical Oncology

2019
AO Cuneo

Cremolini C; Antoniotti C; Lonardi S; Rossini D; Pietrantonio F; Cordio SS; Bergamo F; Marmorino F; Maiello E; Passardi A; Masi G; Tamburini E; Santini D; Grande R; Zaniboni A; Granetto C; Murgioni S; Aprile G; Boni L; Falcone A;

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2018 Jul;29(7):1528-1534. doi: 10.1093/annonc/mdy140. Epub 2018 Apr 20.

2018
AO Cuneo
AOU Città della Salute di Torino

Zagonel V; Sensi E; Masi G; Granetto C; Allegrini G; Buonadonna A; Marmorino F; Tonini G; Zaniboni A; Loupakis F; Racca P; Ronzoni M; Moretto R; Tomasello G; Bergamo F; Cortesi E; Lonardi S; Antoniotti C; Cremolini C; Fontanini G; Boni L; Falcone A;

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. in Oncotarget / Oncotarget. 2017 Dec 21;9(8):7859-7866. doi: 10.18632/oncotarget.23559. eCollection 2018 Jan 30.

2018
AOU Città della Salute di Torino
AO Cuneo

Boni L; Zagonel V; Di Donato S; Ricci V; Allegrini G; Buonadonna A; Racca P; Zaniboni A; Tomasello G; Ronzoni M; Moretto R; Cortesi E; Citi V; Marmorino F; Borelli B; Loupakis F; Bergamo F; Lonardi S; Antoniotti C; Del Re M; Cremolini C; Falcone A; Danesi R;

Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2018 Apr 1;29(4):924-930. doi: 10.1093/annonc/mdy004.

2018
AO Cuneo
AOU Città della Salute di Torino

Santini D; Boni L; Falcone A; Tomcikova D; Tonini G; Chiara S; Di Donato S; Allegrini G; Fea E; Buonadonna A; Racca P; Tomasello G; Zaniboni A; Ronzoni M; Urbano F; Schirripa M; Marmorino F; Stellato M; Masi G; Lonardi S; Bergamo F; Zeppola T; Cremolini C; Dell'Aquila E;

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. in ESMO open / ESMO Open. 2018 Jul 9;3(4):e000403. doi: 10.1136/esmoopen-2018-000403. eCollection 2018.

2018
AO Cuneo

Falcone A; Boni L; Cremolini C; Delliponti L; Vitello S; Antonuzzo L; Martinelli E; Vannini F; Marsico VA; Colombo C; Granetto C; Leone F; Passardi A; Boccaccino A; Pella N; Di Battista M; Martignetti A; Zaniboni A; Zucchelli G; Salvatore L; Rossini D; Marmorino F; Burgio V; Masi G; Pietrantonio F; Bonetti A; Antoniotti C; Lonardi S; Borelli B; et alii...

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. in BMC cancer / BMC Cancer. 2017 Jun 9;17(1):408. doi: 10.1186/s12885-017-3360-z.

2017
AO Cuneo

Santini D; Allegrini G; Di Donato S; Passardi A; Tomasello G; Valsuani C; Pietrantonio F; Ronzoni M; Ricci V; Tamburini E; Aprile G; Lonardi S; Zagonel V; Boni L; Schirripa M; Salvatore L; Antoniotti C; Masi G; Loupakis F; Marmorino F; Cremolini C; Falcone A;

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. in British journal of cancer / Br J Cancer. 2017 Jan;116(3):318-323. doi: 10.1038/bjc.2016.413. Epub 2017 Jan 12.

2017
ASL Biella
AO Cuneo

Cremolini C; Falcone A; Boni L; Tomcikova D; Paris M; Bonetti A; Martignetti A; Dargenio F; Miraglio E; Amoroso D; Banzi MC; Borelli B; Chiara S; Loupakis F; Masi G; Allegrini G; Barbara C; Salvatore L; Antonuzzo L; Marmorino F;

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2016 May;27(5):843-9. doi: 10.1093/annonc/mdw052. Epub 2016 Feb 9.

2016
AO Cuneo
AOU Città della Salute di Torino

Cremolini C; Loupakis F; Masi G; Lonardi S; Granetto C; Mancini ML; Chiara S; Moretto R; Rossini D; Vitello S; Allegrini G; Tonini G; Bergamo F; Tomasello G; Ronzoni M; Buonadonna A; Bustreo S; Barbara C; Boni L; Falcone A;

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2015 Jun;26(6):1188-1194. doi: 10.1093/annonc/mdv112. Epub 2015 Feb 23.

2015
AO Cuneo
AOU Città della Salute di Torino

Cremolini C; Loupakis F; Antoniotti C; Lonardi S; Masi G; Salvatore L; Cortesi E; Tomasello G; Spadi R; Zaniboni A; Tonini G; Barone C; Vitello S; Longarini R; Bonetti A; D'Amico M; Di Donato S; Granetto C; Boni L; Falcone A;

Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial. in JAMA / JAMA. 2015 Dec 22-29;314(24):2632-40. doi: 10.1001/jama.2015.17291.

2015
AO Cuneo

Boni L; Del Mastro L; Sertoli MR; Pronzato P; Vecchio C; Bighin C; Poggio F; Giraudi S; Giordano M; Gamucci T; Scotto T; Levaggi A; Garrone O; Gori S; Michelotti A; Lambertini M;

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2015 Apr;26(4):724-730. doi: 10.1093/annonc/mdv012. Epub 2015 Jan 18.

2015
AO Cuneo

Falcone A; Amoroso D; Bonetti A; Chiara S; Allegrini G; Boni C; Fea E; Antonuzzo L; Granetto C; Barbara C; Safina V; Cupini S; Schirripa M; Cremolini C; Fornaro L; Boni L; Masi G; Loupakis F; Salvatore L;

The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. in PloS one / PLoS One. 2015 Sep 4;10(9):e0136731. doi: 10.1371/journal.pone.0136731. eCollection 2015.

2015
ASL Cuneo 1
AO Cuneo
AOU Novara

Mentuccia L; Laudadio L; Zoboli A; Marchetti F; Bogina G; Lunardi G; Boni L; Gamucci T; Evangelisti L; Barni S; Saracchini S; Amaducci L; Santini D; Fabi A; Garrone O; Frassoldati A; Cavanna L; Saggia C; Bria E; Cretella E; Vici P; Spazzapan S; Iezzi L; De Simone V; Duranti S; Cavazzini MG; Turazza M; Gubiotti M; Foglietta J; et alii...

Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study in Journal of Clinical Oncology

2014
AO Cuneo

Loupakis F; Cremolini C; Lonardi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Valsuani C; Chiara S; Boni C; Marcucci L; Negri F; Barone C; Vitello S; D'Amico M; Granetto C; Fontanini G; Tomcikova D; Boni L; Falcone A;

Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III “BEBYP” trial by the Gruppo Oncologico Nord Ovest (GONO) in Journal of Clinical Oncology

2013
AO Cuneo

Masi G; Loupakis F; Salvatore L; Cremolini C; Fornaro L; Schirripa M; Granetto C; Miraglio E; Di Costanzo F; Antonuzzo L; Marcucci L; Barbara C; Boni C; Banzi M; Chiara S; Garbarino D; Valsuani C; Bonetti A; Boni L; Falcone A;

Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer: A pooled analysis of two randomized trials in Journal of Thoracic Oncology

2011
AO Cuneo

Tiseo M; Ardizzoni A; Boni L; Vincent A; Buti S; Camerini A; Labianca R; Genestreti G; Zanelli F; Ciuffreda L; Di Costanzo F; De Marinis F; Crino L; Santo A; Pazzola A; Barbieri F; Zilembo N; Colantonio I; Tibaldi C; Smit EF;